The serotonin 1A (5-HT1A) receptor as a pharmacological target in depression
Clinical depression is a common, debilitating and heterogenous disorder. Existing treatments for depression are inadequate for a significant minority of patients and new approaches are urgently needed. A wealth of evidence implicates the serotonin 1A (5-HT1A) receptor in the pathophysiology of depre...
Автори: | Smith, ALW, Harmer, CJ, Cowen, PJ, Murphy, SE |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Springer Nature
2023
|
Схожі ресурси
Схожі ресурси
-
Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial
за авторством: de Cates, AN, та інші
Опубліковано: (2024) -
Translating the promise of 5HT4 receptor agonists for the treatment of depression
за авторством: Murphy, SE, та інші
Опубліковано: (2020) -
Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research
за авторством: Colwell, MJ, та інші
Опубліковано: (2022) -
Pharmacological characterization of a 5-HT1-type serotonin receptor in the red flour beetle, Tribolium castaneum.
за авторством: Rut Vleugels, та інші
Опубліковано: (2013-01-01) -
Déjà-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task
за авторством: de Cates, AN, та інші
Опубліковано: (2021)